This approval establishes the use of Olaparib in combination with Durvalumab as a maintenance treatment for adult patients with advanced or recurrent endometrial cancer. It is indicated for those whose disease has not progressed following first-line treatment with Durvalumab combined with platinum-based chemotherapy, the company said. The receipt of this permission paves way for the launch of Olaparib film-coated tablets 100 mg & 150 mg (Lynparza) in India. AstraZeneca Pharma India is engaged in the business of manufacture, distribution, and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. AstraZeneca Pharma tumbled 5.12% to Rs 6,768 after the pharmaceutical firm's net profit declined 26.62% to Rs 38.43 crore in Q2 FY25 as compared with Rs 52.37 crore posted in Q2 FY24. Revenue from operations jumped 31.16% year on year (YoY) to Rs 408 crore in the quarter ended 30 September 2024. The counter shed 0.14% to Rs 6,446.55 on the BSE.Powered by Capital Market - Live

Earlier, on 2 December 2023, the pharma company intimated about the receipt of import and market permission from the Drugs Controller General of India in Form CT-20 for Budesonide Ph. Eur 160 mcg+ Glycopyrronium Ph. Eur 7.2 mcg+ Formoterol Fumarate Dihydrate Ph. Eur 5 mcg inhalation preparations (Breztri Aerosphere). Breztri Aerosphere is indicated for maintenance treatment to relieve symptoms and prevent exacerbations in adult patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Pharma India is engaged in the business of manufacture, distribution, and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. The pharmaceutical firm's net profit declined 26.62% to Rs 38.43 crore in Q2 FY25 as compared with Rs 52.37 crore posted in Q2 FY24. Revenue from operations jumped 31.16% YoY to Rs 408 crore in the September 2024 quarter.Powered by Capital Market - Live

The key domestic indices traded sideways in early afternoon trade. The Nifty traded above the 23,550 mark. Barring FMCG index all the indices on the NSE were traded in green. At 13:25 IST, the barometer index, the S&P BSE Sensex, was down 61.39 points or 0.08% to 77,629.56. The Nifty 50 index added 0.70 points or 0.0% to 23,558.35. The broader market outperformed the benchmark indices. The S&P BSE Mid-Cap index gained 0.88% and the S&P BSE Small-Cap index jumped 1.38%. The market breadth was positive. On the BSE, 2,297 shares rose and 1,573 shares fell. A total of 100 shares were unchanged. Economy: The annual rate of inflation based on all India Wholesale Price Index (WPI) number is 2.36% (Provisional) for the month of October, 2024 (over October, 2023). Inflation in October, 2024 is primarily due to increase in prices of food articles, manufacture of food products, other manufacturing, manufacture of machinery & equipment, manufacture of motor vehicles, trailers & semi-trailers, etc. The month-on-month change in WPI for October 2024 showed a rise of 0.97% compared to September 2024. Gainer & Losers: Eicher Motors (up 7.20%), Hero Motocorp (up 1.97%), Hindalco Industries (up 0.25%), Coal India (up 1.18%) and Reliance Insudtries (up 1.17%) were major Nifty gainers. Eicher Motors jumped 7.20% after the company's consolidated net profit increased 8.27% to Rs 1,100.33 crore on 3.8% increase in revenue from operations to Rs 4,186.38 crore in Q2 FY25 over Q2 FY24. Hindustan Unilever (down 3%), Bharat Petroleum Corporation (BPCL) (down 2.11%), Britannia Industries (down 2.04%), Shriram Finance (down 1.93%) and Tata Consumer Products (down 1.89%) were major Nifty losers. Stocks in Spotlight: Varun Beverages added 1.44% after the company's board has approved the opening of qualified institutional placement (QIP) of equity shares with the floor price of Rs 594.56 per share. Apollo Tyres rallied 4%. The company reported 37.27% decline in consolidated net profit to Rs 297.46 crore in Q2 FY25 as against Rs 474.25 crore recorded in Q2 FY24. However, revenue from operations grew by 2.50% to Rs 6,437.03 crore in the quarter ended 30 September 2024. SpiceJet jumped 4.36% after the firm fully settled a $90.8 million (Rs 763 crore) dispute with Export Development Canada (EDC) for a total of $22.5 million, resulting in a substantial saving of $68.3 million (Rs 574 crore). Vodafone Idea rose 0.14%. The telecom service provider's consolidated net loss narrowed to Rs 7,175.9 crore in Q2 FY25 as compared with Rs 8,737.9 crore reported in Q2 FY24. Revenue from operations rose 2.01% year on year (YoY) to Rs 10,932.2 crore in the quarter ended 30 September 2024. Godrej Industries added 0.55%. The company's consolidated net profit surged 229.5% to Rs 287.62 crore in Q2 FY25 as compared with Rs 87.30 crore in Q2 FY24. Revenue from operations jumped 22% YoY to Rs 4,804.96 crore in Q2 FY25. AstraZeneca Pharma tumbled 4.37% after the pharmaceutical firm's net profit declined 26.62% to Rs 38.43 crore in Q2 FY25 as compared with Rs 52.37 crore posted in Q2 FY24. Global Markets: Most of the European stocks advanced as investors assessed the global inflation outlook and the possible trajectory of central bank rate cuts. The initial post-election rally in US equities appears to be waning. On Wednesday, the Dow Jones Industrial Average added 0.11%, while the S&P 500 index climbed 0.02%, and the NASDAQ Composite index lost 0.23%. US consumer price index (CPI) data for October came in line with expectations, but still indicated persistent inflationary pressures. The annual CPI rose to 2.6% from 2.4% in September. Core CPI, which excludes volatile food and energy prices, increased to 3.3% year-over-year. While these figures still support the case for a December rate cut by the Federal Reserve, the longer-term outlook for interest rates remains uncertain, especially given the potential inflationary impact of Trump's policies. Investors are now awaiting a speech by Fed Chair Jerome Powell for further guidance on monetary policy. The Fed cut rates by 25 basis points last week and reaffirmed its data-dependent approach to future easing.Powered by Capital Market - Live

Revenue from operations jumped 31.16% year on year (YoY) to Rs 408 crore in the quarter ended 30 September 2024, by increase in demonstrating company's focus on improving access to patients. Profit before exceptional items and tax stood at Rs 51.03 crore in second quarter of FY25, down 10.4% YoY. The firm reported exceptional profit of Rs 16.43 crore in Q2 of FY24. Total expenses spiked 39.1% YoY to Rs 365.12 crore in Q2 FY25. Cost of material consumed was at Rs 77.15 crore (up 98.84% YoY) while employee benefit expenses were at Rs 68.04 crore (up 4.24% YoY) during the period under review. Bhavana Agrawal, chief financial officer, AstraZeneca Pharma India, said, 'We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31% bringing our H1 revenue from operations to Rs 7,955.2 million, driven by our portfolio -oncology, biopharmaceuticals and rare disease. The growth of the company is a derivative of our ambition to bring innovative medicines faster in the country for unmet patient needs.' Dr. Sanjeev Panchal, country president & managing director, AstraZeneca Pharma India, said 'We are transforming the future of healthcare by unlocking the power of what science can do, for people, society, and planet. With a growth through Innovation strategy, we are constantly working towards expanding access to innovative therapies, progressive access strategies, and making healthcare systems resilient in India.' AstraZeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Powered by Capital Market - Live

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live

Sapphire Foods India Ltd, Godawari Power & Ispat Ltd, Firstsource Solutions Ltd and National Aluminium Company Ltd are among the other gainers in the BSE's 'A' group today, 24 September 2024.Astrazeneca Pharma India Ltd soared 11.61% to Rs 7530 at 11:48 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 20901 shares were traded on the counter so far as against the average daily volumes of 934 shares in the past one month. Sapphire Foods India Ltd spiked 8.65% to Rs 382.9. The stock was the second biggest gainer in 'A' group. On the BSE, 1.22 lakh shares were traded on the counter so far as against the average daily volumes of 51731 shares in the past one month. Godawari Power & Ispat Ltd surged 7.08% to Rs 1058.6. The stock was the third biggest gainer in 'A' group. On the BSE, 1.47 lakh shares were traded on the counter so far as against the average daily volumes of 24647 shares in the past one month. Firstsource Solutions Ltd exploded 5.35% to Rs 331.7. The stock was the fourth biggest gainer in 'A' group. On the BSE, 7.64 lakh shares were traded on the counter so far as against the average daily volumes of 2.51 lakh shares in the past one month. National Aluminium Company Ltd jumped 5.16% to Rs 189.6. The stock was the fifth biggest gainer in 'A' group. On the BSE, 12.25 lakh shares were traded on the counter so far as against the average daily volumes of 5.09 lakh shares in the past one month. Powered by Capital Market - Live

Durvalumab (IMFINZI) in combination with chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, is indicated for the treatment of patients with resectable (tumours 4 cm and/or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. The receipt of this permission paves way for the launch of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion (Imfinzi) in India. AstraZeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. The pharmaceutical firm reported net loss of Rs 11.79 crore in Q1 FY25 as compared to net profit of Rs 53.86 crore recorded in Q1 FY24. Revenue from operations jumped 31.15% year on year (YoY) to Rs 387.52 crore in the quarter ended 30 June 2024 The counter declined 1.69% to ends at Rs 6,746.45 on Monday, 23 September 2024.Powered by Capital Market - Live

Revenue from operations jumped 31.15% year on year (YoY) to Rs 387.52 crore in the quarter ended 30 June 2024, by increase in demonstrating company's focus on improving access to patients. Profit before exceptional items and tax stood at Rs 42.4 crore in first quarter of FY25, down 40.62% from Rs 71.4 crore posted in Q1 FY24. The firm reported exceptional loss of Rs 57.56 crore during the quarter. Total expenses spiked 52.25% YoY to Rs 353.47 crore in Q1 FY25. Cost of material consumed was at Rs 45.85 crore (up 140.3% YoY) while employee benefit expenses were at Rs 60.96 crore (down 10.9% YoY) during the period under review. Dr. Sanjeev Panchal, country president and managing director, AstraZeneca India, commented, 'We are pleased to report a strong financial performance this quarter. It reflects our continuous endeavour of harnessing science and commitment to bringing innovative medicines faster to India. We are focused on our ambition to ensure our therapies reach the patients who need them the most and are constantly working to tailor sustainable programs focused on early diagnosis and improved access to meet local needs by collaborating with healthcare systems, payers, policymakers, and non-government organizations.' Bhavana Agrawal, chief finance officer, added, It's a strong start of the year with 31% revenue growth and double-digit profit margin (before exceptional item and tax). The results are an outcome of company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years. We are continuously pushing the boundaries of science and are well positioned for consistent value creation for our customers and shareholders.' AstraZeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Powered by Capital Market - Live

Net loss of Astrazeneca Pharma India reported to Rs 11.79 crore in the quarter ended June 2024 as against net profit of Rs 53.86 crore during the previous quarter ended June 2023. Sales rose 31.15% to Rs 387.52 crore in the quarter ended June 2024 as against Rs 295.47 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales387.52295.47 31 OPM %9.8222.76 - PBDT46.3175.19 -38 PBT42.4071.40 -41 NP-11.7953.86 PL Powered by Capital Market - Live